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Abstract 
The quantitative analysis of different brands of Amlodipine tablets was carried out (using HPLC and 
U.V Spectrophotometer) to determine if the drugs are of required standards. The results obtained from analysis 
of the various drugs were compared with that of the standard. The percentage content for each sample was 
calculated using the absorbance and peak areas of the samples and that of the standard to see if they are within 
specified limit as stated by the official books. Amlodipine has a range of 97%-102% according to B.P 2008, 
From the result obtained using UV – Spectrophotometer,A (98.3%), B (100%),E (101.8%),F (101.22%),I 
(100.8%) are all within the B.P Specified limit while D (88.65%),G (65.57%) and C are said to be below the B.P 
specified limit. From the result obtained using HPLC analysis G (101.5% and A (100%) are said to be within the 
specified limit but E (441.8%), I (90.4%),H (92.2%) and F (95.4%) are all below the B.P specified limit while B 
(104.3%),C (126.2%) and D (201.8%) are said to be above the B.P specified limit. using UV- spectrophotometry 
shows that 5 samples of the Amlodipine passed and 4 samples failed while for HPLC, only 2 samples passed 
KEYWORDS: Amlodipine, UV, HPLC 
 
1. Introduction 
 The science of drug analysis is an extensively active one in terms of research and development of new, 
more reliable or more sensitive methods that have become of great importance in the analysis and quality control 
of drug and drug products at every stage of their life. A whole arsenal of chemical, physicochemical and 
automated analytical techniques is now available for determining the identity, purity, content, stability, safety 
and efficacy of drugs and their formulations. Thus in the development, formulation, marketing and 
pharmacokinetic assessment of a drug, the analyte is involved in several diverse areas including the following: 
1) Determination of identity and purity of starting materials used in the manufacturing of the drug substance. 
2) Test for identity and purity of the drug. 
3) Isolation and identification of trace impurities of the drug. 
4) Determination of degradation rates and degradation products of the drug. 
5) Identification of the drug in a formulated product and its qualitative analysis. 
6) Determination of any degradation within the formulated product and possible isolation of substance for toxicity 
test. 
7) Evaluation of content uniformity for low dose formulations (Ajibola, 2000). 
This deals with the study of the nature or the quality of the compound or mixture. It also involves the 
identification of constituent radicals present in the organic mixture (Ahmad and Ali, 2009) 
 
 A Clinical study was carried out in 2010 on The Effect of Amlodipine Alone and in Combination with 
Atenolol on Bowel Habit in Patients with Hypertension and showed the following result A total of 100 patients 
who attended the hypertensive clinic in Government Medical College and Hospital, Chandigarh, were included 
in the study after the screening. Fifty patients were on amlodipine alone and 50 patients were on combination of 
amlodipine and atenolol. The number of patients in the amlodipine group with SBM/wk less than 3 was 8 
whereas in combination group (amlodipine + atenolol) it was 2 (P = .045, Fisher’s exact test, significant). The 
relative risk (RR) of developing constipation was 4.00 with 95% CI 0.8930 to 17.917 in amlodipine alone group. 
However, there was no significant difference in SBM/wk in both the groups before and after treatment (P > .05). 
Advances in Life Science and Technology                                                                                                 www.iiste.org 
ISSN 2224-7181 (Paper) ISSN 2225-062X (Online) 
Vol.27, 2014 
 
51 
The majority of the patients in both the groups were on amlodipine 10 mg daily dose (28(56%) patients in 
amlodipine group and 29(58%) patients in combination group). The duration of treatment with amlodipine was 
also comparable in both the groups (16.75 ± 2.5 months versus 14.025 ± 2.58 months). The number of patients 
with blood in stool was 5 in amlodipine group while there was none in the combination group (P =  .028, 
significant). Straining/hard stool was seen in 10 patients in the amlodipine group and 3 patients in the 
combination group (P = .035, significant). The risk (RR = 3.33 with 95% CI 0.9748 to11.399) of developing 
hard stool. So from the present observation, it can be said that amlodipine alone associated with increased 
incidence of constipation (RR = 4.00) and hard stool (RR = 3.333) and when atenolol was combined, the 
incidence of constipation and hard stool was less (P < .05). SBM: spontaneous bowel movement. Results are 
expressed as mean ± SD and absolute number (Lekha and Chander 2011). 
8)   In another study a work was carried out on the Comparative Effects of Amlodipine and Cilnidipine on 
Sympathetic Nervous Modulation in Patients With Hypertension and showed the following in their Results: In 
patients with continuous amlodipine treatment, systolic and diastolic blood pressures (SBP, DBP) and heart rate 
(HR) remained unchanged. LF/HF and HF/TP ratios also remained unchanged (LF/HF 1.77±1.05 vs. 1.83±1.22, 
HF/TP 0.419±0.122 vs. 0.402±0.116). Plasma norepinephrine levels were comparable (370±88 pg/ml vs. 
491±137 pg/ml). In patients switched to cilnidipine, SBP, DBP and HR were similar before and after switching. 
Interestingly, LF/HF ratio decreased significantly (p = 0.012) from 2.37±1.56 to 1.89±1.42, and HF/TP ratio 
increased significantly (p = 0.049) from 0.366±0.132 to 0.417±0.156, despite the comparable HR. Plasma 
norepinephrine concentrations decreased significantly (p = 0.009) from 359±65 pg/ml to 282±72 pg/ml (Ikai A. 
et al., 2010). 
 
1.1 Amlodipine 
Amlodipine (as besylate, mesylate or maleate) is a long-acting calcium channel blocker dihydropyridine 
(DHP) class used as an antihypertensive and in the treatment of angina pectoris. Like other calcium channel 
blockers, amlodipine acts by relaxing the smooth muscle in the arterial wall, decreasing total peripheral  
resistance thereby reducing blood pressure; in angina, Amlodipine increases blood flow to the heart muscle 
(although DHP-class calcium channel blockers are more selective for arteries than the muscular tissue of the 
heart (myocardium), as the cardiac calcium channels are not of the dihydropyridine-type). 
Amlodipine 
 
(Wikipedia) 
Chemical data 
Formula 
 
 
C20H25ClN2O5  
Mol. mass  408.879 g/mol 
(Bertram G. Katzung, 2001) 
1.2 Medical uses 
Amlodipine is used in the management of hypertension and coronary artery disease and stroke (Wang, J.G., 
2009)  
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2. Materials and Method 
Nine (9) brands of Amlodipine were used for the study 
Pure sample of the drugs were obtained from NAFDAC which served as standard 
Writing and labeling materials, Measuring cylinder, Beakers, 1000ml volumetric flask, 100ml volumetric flask, 
50ml volumetric flask, Sonicator, Filter paper, Spatula, High performance liquid chromatography set up, UV 
Visible spectrophotometer (Beckman), Analytical weighing balance, Pestle and mortar, Distilled water 
All reagents used were obtained from NAFDAC office, Maiduguri. (Sani et al, 2011)1 
2.1 Practical Method 
The methods employed for the purpose of this study are the UV visible spectrophotometer and high 
performance liquid chromatographic methods. (Sani et al, 2011)2 
2.2 UV Procedure for Amlodipine (BP, 2008) 
The tablets were assayed spectrophotometrically using the following procedures 
- The average weight of the tablets from each sample was determined by weighing ten(10) tablets and dividing the 
results gotten by nine to obtain the average weight 
- From the value gotten the equivalent weight of each brand was weighed accurately and transfered into 100ml 
volumetric flasks. All the nine samples were labelled using pen and masking tape. 
- To each volumetric flask, 60ml of 0.01M sodium dihydrogen phosphate buffer and acetonitrile (63:37) was 
poured and sonicated for few minutes to dissolve the drug molecule. 
-  The mixture in each flask was mixed well and filtered through a filter paper into clean beakers. 
- The UV spectrophotometer was put at zero by running a base line using diluents as blank. 
- The absorbance of each sample was determined at the peak wavelength by putting small amount of the sample 
into a cuvette, and the cuvette was put back into the machine. 
- The same procedure was repeated for the standard using 5mg of the powdered standard and the absorbance 
determined and from which the % content and mg content was determined as: 
% content = Absorbance of sample x 100 
          Absorbance of standard 
 
Mg content = % content x  Manufactures claim 
100 
2.3 HPLC Procedure for Amlodipine 
Mobile phase 
 Prepare a solution of 0.01M solution dihydrogen phosphate buffer and acetonitrile (63:37 v/v) in 100ml 
volumetric flask. Adjust the PH to 3.5 
Chromatographic system 
 The liquid chromatograph is equipped with a 237nm detector and a 150cm x 4.6mm column that 
contains packing L1. The flow rate is about 1.5ml/minute 
Procedure: 
- The average weight of the tablets from each sample was determined by weighing ten(10) tablets and dividing the 
results gotten by nine to obtain the average weight 
- From the value gotten the equivalent weight of each brand was weighed accurately and transferred into 100ml 
volumetric flasks. All the nine samples were labelled using pen and masking tape. 
- To each volumetric flask, 60ml of the mobile phase was poured and sonicated for few minutes to dissolve the 
drug molecule. 
-  The mixture in each flask was mixed well and filtered through a filter paper into clean beakers. 
- The same procedure was repeated for the standard using 5mg of the powdered standard  
- Separately inject equal volume of the standard preparation and the assay preparation into the chromatograph, 
record the chromatograms, and measure the responses for the major peaks. Calculate the quantity in mg of 
Amlodipine. (Sani et al, 2012) 
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-  
3. Results 
Table 1 Brand Name of some Amlodipine  
Brand Name Brand Code 
Amlodipine A 
Cadrex B 
Orkal  C 
Juvasc D 
Amlong E 
Tenox F 
Amnivasc G 
Miravase H 
Acedipine I 
 
The data below shows the result of UV spectrophotometer which is used to calculate the percentage and 
milligram content of the following drugs. 
The results are as follows: 
 
3.1. Amlodipine 
A  
%content = 321.00 x 100 = 98.3% 
     326.29 
` Mg content = 98.3  x 5 = 4.9mg 
                  100 
     B 
%content = 326.29 x 100 = 100% 
       326.29 
     Mg content = 100  x 5 = 5mg 
              100 
     C 
%content = 311.29 x 100 = 95.4% 
       326.29 
  Mg content = 95.4  x 5 = 4.77mg 
                  100 
  D 
%content = 289.26 x 100 = 88.65% 
           326.29 
      Mg content = 88.65  x 5 = 4.4mg 
                100 
E 
%content = 332.241 x 100 = 101.8% 
         326.29 
Mg content = 101.8  x 5 =5.09mg 
                100 
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F 
 %content = 330.29 x 100 = 101.22% 
       326.29 
     Mg content = 101.22  x 5 = 5.06mg 
              100 
G 
 %content = 213.94 x 100 = 65.57% 
       326.29 
     Mg content = 65.57  x 5 = 3.28mg 
               100 
H 
 %content = 405.83 x 100 = 124.38% 
      326.29 
Mg content = 124.38  x 5 = 6.2mg 
                 100 
I 
%content = 328.92 x 100 = 100.8% 
      326.29 
Mg content = 100.8  x 5 = 5.04mg 
                100 
Table 2: UV absorbance for amlodipine at a wavelenght of 237nm 
Sample                                                                         Absorbance (A) 
A                                                                                       321.00 
B                                                                                       326.29                                        
C                                                                                       311.29 
D                                                                                       289.26 
E                                                                                        332.241 
F                                                                                        330.29 
G                                                                                        213.94 
H                                                                                        405.83 
I                                                                                          328.92 
 
Table 3: Percentage content and mg content of different brands of Amlodipine using UV 
Sample                             %content                                          mg content 
A                                     98.3                                                     4.9 
B                                     100                                                      5 
C                                     95.4                                                     4.77 
D                                    88.65                                                   4.4 
E                                    101.8                                                   5.09 
F                                     101.22                                                 5.06 
G                                    65.57                                                  3.28 
H                                    124.3                                                   6.2 
I                                     100.8                                                   5.04 
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3.2 HPLC for Amlodipine 
Figure 1:  
Analyst:  manager  
Sample ID:  G 030513MEOH    Vial:  119    Injection Volume:  20  
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  6.017 4332964 100.000 MM 
     
Totals     
  4332964 100.000  
 
% content = 4332964 x 100 = 101.5% 
      4268878 
 
Mg content = 101.5 x 5 = 5.1mg 
         100 
 
Figure 2: 
Analyst:  manager  
Sample ID:  A 030513MEOHRPT    Vial:  139    Injection 
Volume:  20  
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  6.003 4268879 100.000 MM 
     
Totals     
  4268879 100.000  
 
% content = 4268879 x 100 = 100% 
       4268878 
 
 
Mg content = 100 x 5 = 5mg 
        100 
 
Figure 3: 
Analyst:  manager  
Sample ID:  E 020513MEOH    Vial:  149    Injection Volume:  20  
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  5.977 1782769 99.997 MM 
  9.913 61 0.003 IB 
     
Totals     
  1782830 100.000  
 
% content = 1782769 x 100 = 41.8% 
        4268878 
Mg content = 41.8 x 5 = 2.1mg 
        100 
 
Figure 4: 
Analyst:  manager  
Sample ID:  I 030513MEOH    Vial:  109    Injection Volume:  20  
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  0.080 271 0.007 BI 
  6.040 3859801 99.993 MM 
     
Totals     
  3860072 100.000  
 
% content = 3859801 x 100 = 90.4% 
       4268878 
 
Mg content = 90.4 x 5 = 4.5mg 
        100 
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Figure 5: 
Analyst:  manager  
Sample ID:  B 020513MEOH    Vial:  189    Injection Volume:  20  
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  5.937 4451622 100.000 MM 
  9.907 2 0.000 BE 
     
Totals     
  4451624 100.000  
 
% content = 4451622 x 100 = 104.3% 
       4268878 
 
Mg content = 104.3 x 5 = 5.2mg 
          100 
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Figure 6: 
Analyst:  manager  
Sample ID:  H 020513MEOH    Vial:  199    Injection Volume:  20  
Minutes
0 1 2 3 4 5 6 7 8 9 10
m
AU
0
10
20
30
m
AU
0
10
20
30
0.
06
3
5.
91
7
UV-VIS
Retention Time
 
 
UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  0.063 211 0.005 BI 
  5.917 3937713 99.995 MM 
     
Totals     
  3937924 100.000  
 
% content = 3937713 x 100 = 92.2% 
      4268878 
 
Mg content = 92.2 x 5 = 4.6mg 
        100 
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Figure 7: 
Analyst:  manager  
Sample ID:  C 020513MEOH    Vial:  159    Injection Volume:  20  
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  5.957 5387262 100.000 MM 
     
Totals     
  5387262 100.000  
 
% content = 5387262  x 100 = 126.2% 
       4268878 
 
Mg content = 126.2 x 5 = 6.3mg 
            100 
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Figure 8: 
Analyst:  manager  
Sample ID:  D 030513MEOH    Vial:  129    Injection Volume:  20  
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  5.980 8612299 100.000 MM 
     
Totals     
  8612299 100.000  
 
% content = 8612299 x 100 = 201.8% 
        4268878 
 
Mg content = 201.8 x 5 = 10.1mg 
          100 
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Figure 9: 
Analyst:  manager  
Sample ID:  F 030513MEOH    Vial:  99    Injection Volume:  20  
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UV-VIS Results     
Name Retention Time Area Area Percent Integration Codes 
  6.020 4071402 100.000 MM 
     
Totals     
  4071402 100.000  
 
% content = 4071402 x 100 = 95.4% 
           4268878 
 
Mg content = 95.4 x 5 = 4.8mg 
    100 
 
Table 4: Percentage content and mg content of different brands of Amlodipine using HPLC 
SAMPLE                                          %CONTENT                           Mg CONTENT 
G                                                   101.5%                                       5.1mg 
E                                                    41.8%                                         2.1mg 
I                                                     90.4%                                         4.5mg 
B                                                    104.3%                                      5.2mg 
H                                                    92.2%                                         4.6mg 
C                                                    126.2%                                       6.3mg 
D                                                    201.8%                                       10.1mg 
F                                                    95.4%                                        4.8mg     
A                                                   100%                                          5mg                          
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4. DISCUSSION 
According to British Pharmacopoeia, Amlodipine tablet should contain not less than 97% and not more than 
102.0% of A. The standard Amlodipine has an absorbance 326.29 at the wavelength of 237nm. 
From the result obtained using UV – Spectrophotometer,A (98.3%), B (100%),E (101.8%),F 
(101.22%),I (100.8%) are all within the B.P Specified limit while D (88.65%),G (65.57%) and C are said to be 
below the B.P specified limit. 
        From the result obtained using HPLC analysis G (101.5% and A (100%) are said to be within the specified 
limit but E (441.8%), I (90.4%),H (92.2%) and F (95.4%) are all below the B.P specified limit while B 
(104.3%),C (126.2%) and D (201.8%) are said to be above the B.P specified limit. 
5. CONCLUSION 
 For Amlodipine following BP specification, it can be concluded that 5 brands of the drug passed and 4 
brands of the drug failed while for HPLC analysis only 2 brands passed. 
6. RECOMMENDATION 
Pharmaceutical analysis should always be carried out on Drugs by regulatory bodies to ensure that 
drugs that are being marketed are of the required standard to eradicate the problems of fake and counterfeit drugs 
and also guilty companies should be queried or closed down as appropriate. 
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